Sai Parenterals & Gravita India Announce Expansions

Corporate expansion moves are taking center stage as companies deploy capital into targeted acquisitions and international subsidiaries. Sai Parenterals and Gravita India have both announced strategic initiatives to accelerate growth across their respective sectors.

Sai Parenterals Secures Research Capabilities

Sai Parenterals completed the acquisition of a controlling interest in Prathyak Laboratories to bolster its research and development framework. The transaction redirects capital from previous greenfield allocations toward an operational facility in Genome Valley.

• Acquisition Stake: 60% equity stake acquired in Prathyak Laboratories
• Transaction Value: Rs 15 crore funded from unutilised initial public offering proceeds
• Target Renaming: Prathyak is now a direct subsidiary renamed as Sai Prathyak Laboratories
• Future Option: Remaining 40% stake subject to a Right of First Refusal at the same valuation

The acquired entity brings three years of operational experience along with 28 research scientists and a development pipeline of 150 SKUs across 86 molecules. These capabilities directly support the company’s focus on lyophilised, liposomal, and nano-based complex injectables.

Gravita India Expands US Footprint

Gravita India secured approval to incorporate a wholly owned subsidiary in the United States to enhance its international presence. The new entity will focus specifically on the procurement and trading of scrap materials.

• Subsidiary Focus: Trading of scrap and scrap materials in the United States market
• Subsidiary Structure: Wholly owned corporate entity

These developments highlight how both firms are actively utilizing capital allocation strategies to strengthen their operational reach in targeted global markets.